Ascendis Pharma A/S (ASND) is a Danish biopharmaceutical company whose American Depositary Receipts (ADRs) trade on Nasdaq. The company develops therapies using its TransCon technology platform for rare endocrine diseases. Its lead commercial products are Skytrofa (growth hormone deficiency), Yorvipath (hypoparathyroidism), and Yuviwel (achondroplasia).
A review of 17 individually attributed analyst price targets, each tied to a named firm and dated within the trailing several months, produces an arithmetic mean of about $310.29, rounded to a $310 central target. The range is wide: Canaccord Genuity initiated coverage with a $268 Hold target, while H.C. Wainwright reiterated a $344 Buy. The broader Street is firmly constructive, with the overwhelming majority of ratings Buy or equivalent and only one Hold and no Sell ratings in recent windows.
Bullish targets typically reflect expectations for sustained Yorvipath growth and a maturing pipeline, while the more cautious targets discount execution risk and a contracting innovation outlook after partner exits. Notably, TD Cowen reiterated at $341, Citi at $330, and Jefferies at $330, whereas Morgan Stanley sits near the low end at $273.
With the stock at $256.59, reaching $310 requires an upside of about 20.8% — a substantial move. The share price sits inside a 52-week range of $188.07 to $282.15, meaning the target lies well above the stock's prior peak. Any path to $310 would likely require a break above that $282 area first, followed by sustained momentum.
The fundamental backdrop is strengthening. Street estimates point to revenue of roughly $1.37 billion for 2026, up roughly 90% from 2025, with Yorvipath net sales expected to exceed $1.1 billion this year. The company's normalized price-to-earnings (P/E) ratio is around 20, with a price-to-sales ratio near 13, levels that price in growth but are not extreme for a profitable rare-disease biotech.
The most durable technical reference is the 52-week high near $282, which has acted as resistance. A close above that level would be a meaningful structural signal for bulls. On the downside, the round-number $250 area has provided support in recent sessions, and the $188 low marks the broader risk zone. The long-term structure remains in an uptrend off the 2025 lows, but the stock has yet to establish a decisive breakout above prior highs.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and the target is not a timed forecast. Investors should watch quarterly results, Yorvipath and Yuviwel sales trends, any new TransCon data or partnership updates, analyst revisions, the progress of the buyback, and broader biotech sector conditions. A decisive break above $282 or a slip below $250 would reframe the technical setup.
For traders who want a more systematic view of momentum, Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how an automated, data-driven lens might complement your own research.
Whether ASND can reach $310 depends on execution more than sentiment. The roughly 21% move would require a breakout above the $282 prior high, continued Yorvipath and Yuviwel growth, and renewed confidence in the TransCon pipeline. The $268 to $344 analyst range shows that even constructive analysts disagree sharply on the pace and durability of growth. The $310 central target is best understood as an aggregate of reasonable outcomes, not a forecast, and investors should monitor commercial launches, pipeline news, and the stock's behavior around key technical levels before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ASND has been loosely correlated with PTGX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then PTGX could also see price increases.
| Ticker / NAME | Correlation To ASND | 1D Price Change % | ||
|---|---|---|---|---|
| ASND | 100% | -1.25% | ||
| PTGX - ASND | 37% Loosely correlated | +0.26% | ||
| RYTM - ASND | 37% Loosely correlated | +0.01% | ||
| ORMP - ASND | 37% Loosely correlated | -0.75% | ||
| AMRN - ASND | 35% Loosely correlated | +0.09% | ||
| TARS - ASND | 35% Loosely correlated | +4.22% | ||
More | ||||